199106-13-3

199106-13-3 structure

Name: MJ33
Chemical Name: lithium,[1-hexadecoxy-3-(2,2,2-trifluoroethoxy)propan-2-yl] methyl phosphate
CAS Number: 199106-13-3
Molecular Formula: C₂₂H₄₄F₃O₇P
Molecular Weight: 498.48300
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phospholipase
Create Date: 2017-03-27 23:44:24
Modify Date: 2024-01-11 20:31:36
MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6[1]. MJ33 has a critical effect on inflammatory brain damage[2].

Name	lithium,[1-hexadecoxy-3-(2,2,2-trifluoroethoxy)propan-2-yl] methyl phosphate
Synonyms	IN1224 MJ33 lithium salt MJ33 mj33 lithium salt

Description	MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6[1]. MJ33 has a critical effect on inflammatory brain damage[2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase Research Areas >> Inflammation/Immunology
In Vitro	MJ33, a transition-state analog competitive inhibitor of PLA2, inhibits the degradation of dipalmitoylphosphatidylcholine (DPPC) by ∼50% in both the whole lung and isolated alveolar type 2 cells. In vitro measurement of PLA2 activity in homogenate of lungs or isolated type 2 cells is markedly inhibited by MJ33 when assays at pH 4.0 in Ca2+-free medium but has no effect on Ca2+-dependent PLA2 activity at pH 8.5[3].
In Vivo	MJ33 (0.5 μM/kg ; by tail vein, at 24 h before MCAO) significantly blocks the increase IL-1β, IL-17 and IL-23 in rats stimulated by Prdx6 siRNA treatment[2]. Compared with the Prdx6 siRNA group, combined exposure to Prdx6 siRNA and MJ33 significantly downregulates the mRNA and protein expression of NF-κB, iNOS and COX-2[2]. Animal Model: Adult male Sprague-Dawley rats weighing 270-310 g (middle cerebral artery occlusion (MCAO) group) [2] Dosage: 0.5 μM/kg Administration: By tail vein, at 24 h before MCAO Result: Significantly blocked the increase IL-1β, IL-17 and IL-23 in rats stimulated by Prdx6 siRNA treatment.
References	[1]. Shanshan Y, et al. Phospholipase A2 of Peroxiredoxin 6 Plays a Critical Role in Cerebral Ischemia/Reperfusion Inflammatory Injury. Front Cell Neurosci. 2017 Apr 5;11:99. [2]. Moawad AR, et al. Deficiency of peroxiredoxin 6 or inhibition of its phospholipase A2 activity impair the in vitro sperm fertilizing competence in mice. Sci Rep. 2017 Oct 11;7(1):12994. [3]. Fisher AB, et al. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J Lipid Res. 2005 Jun;46(6):1248-56.

Boiling Point	522.7ºC at 760 mmHg
Molecular Formula	C₂₂H₄₄F₃O₇P
Molecular Weight	498.48300
Flash Point	269.9ºC
Exact Mass	498.29100
PSA	86.86000
LogP	7.63340
Vapour Pressure	2.5E-12mmHg at 25°C
Storage condition	2-8°C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases	S22
RIDADR	NONH for all modes of transport

199106-13-3	1135306-36-3
1007476-63-2	1158522-08-7
886941-35-1	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
888462-29-1	1018584-77-4
1375289-11-4